NYSE:DGX - Quest Diagnostics Stock Price, Price Target & More

$100.79 -0.01 (-0.01 %)
(As of 04/19/2018 06:18 AM ET)
Previous Close$100.80
Today's Range$100.41 - $101.57
52-Week Range$90.10 - $112.96
Volume1.50 million shs
Average Volume1.02 million shs
Market Capitalization$13.67 billion
P/E Ratio17.84
Dividend Yield1.98%
Beta0.7

About Quest Diagnostics (NYSE:DGX)

Quest Diagnostics logoQuest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:DGX
CUSIP74834L10
Phone973-520-2700

Debt

Debt-to-Equity Ratio0.76%
Current Ratio1.24%
Quick Ratio1.15%

Price-To-Earnings

Trailing P/E Ratio17.84
Forward P/E Ratio15.29
P/E Growth1.9

Sales & Book Value

Annual Sales$7.71 billion
Price / Sales1.77
Cash Flow$7.3893 per share
Price / Cash13.64
Book Value$36.35 per share
Price / Book2.77

Profitability

EPS (Most Recent Fiscal Year)$5.40
Net Income$772 million
Net Margins10.00%
Return on Equity15.41%
Return on Assets7.17%

Miscellaneous

Employees45,000
Outstanding Shares135,640,000

How to Become a New Pot Stock Millionaire

Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Thursday, February 1st. Shareholders of record on Wednesday, April 4th will be paid a dividend of $0.50 per share on Wednesday, April 18th. This represents a $2.00 annualized dividend and a yield of 1.98%. The ex-dividend date is Tuesday, April 3rd. This is a positive change from Quest Diagnostics's previous quarterly dividend of $0.45. View Quest Diagnostics' Dividend History.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics declared that its board has approved a stock repurchase program on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 7.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its shares are undervalued.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics (NYSE:DGX) released its earnings results on Thursday, February, 1st. The medical research company reported $1.40 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The medical research company earned $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. Quest Diagnostics had a return on equity of 15.41% and a net margin of 10.00%. The company's revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.31 EPS. View Quest Diagnostics' Earnings History.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, April, 19th 2018. View Earnings Estimates for Quest Diagnostics.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of $6.50-6.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.16.

What price target have analysts set for DGX?

19 brokers have issued 1 year target prices for Quest Diagnostics' shares. Their forecasts range from $86.00 to $123.00. On average, they anticipate Quest Diagnostics' share price to reach $108.50 in the next twelve months. View Analyst Ratings for Quest Diagnostics.

Who are some of Quest Diagnostics' key competitors?

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the folowing people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 61)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 56)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 55)
  • Dr. Jon R. Cohen, Sr. VP & Group Exec. of Diagnostic Solutions (Age 63)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 55)

Has Quest Diagnostics been receiving favorable news coverage?

News stories about DGX stock have trended somewhat positive on Thursday, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Quest Diagnostics earned a media sentiment score of 0.02 on Accern's scale. They also gave media stories about the medical research company an impact score of 45.84 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $100.79.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $13.67 billion and generates $7.71 billion in revenue each year. The medical research company earns $772 million in net income (profit) each year or $5.40 on an earnings per share basis. Quest Diagnostics employs 45,000 workers across the globe.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]


MarketBeat Community Rating for Quest Diagnostics (DGX)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  302 (Vote Outperform)
Underperform Votes:  582 (Vote Underperform)
Total Votes:  884
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Quest Diagnostics (NYSE:DGX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Quest Diagnostics in the last 12 months. Their average twelve-month price target is $108.50, suggesting that the stock has a possible upside of 7.65%. The high price target for DGX is $123.00 and the low price target for DGX is $86.00. There are currently 11 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.422.452.302.32
Ratings Breakdown: 0 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
12 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $108.50$108.5789$105.6842$106.0789
Price Target Upside: 7.65% upside3.76% upside3.95% upside13.78% upside

Quest Diagnostics (NYSE:DGX) Consensus Price Target History

Price Target History for Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018Canaccord GenuityBoost Price TargetBuy -> Buy$113.00 -> $115.00LowView Rating Details
3/14/2018Morgan StanleyUpgradeUnderweight -> Equal Weight$103.00LowView Rating Details
3/7/2018ArgusUpgradeHold -> Buy$104.14 -> $116.00LowView Rating Details
2/13/2018Credit Suisse GroupUpgradeNeutral -> Outperform$107.00MediumView Rating Details
2/1/2018Piper JaffrayReiterated RatingHold$110.00LowView Rating Details
1/29/2018Goldman SachsInitiated CoverageBuy -> Buy$117.00MediumView Rating Details
1/24/2018MizuhoSet Price TargetBuy$113.00LowView Rating Details
1/4/2018Evercore ISIInitiated CoverageIn -> In-Line$103.00LowView Rating Details
11/25/2017Jefferies GroupSet Price TargetHold$98.00LowView Rating Details
10/27/2017KeyCorpReiterated RatingHoldN/AView Rating Details
10/20/2017Wells FargoLower Price TargetMarket Perform$88.00 -> $86.00N/AView Rating Details
10/20/2017CitigroupLower Price TargetNeutral$110.00 -> $98.00N/AView Rating Details
10/17/2017Craig HallumReiterated RatingHold$110.00 -> $100.00N/AView Rating Details
10/15/2017SunTrust BanksSet Price TargetHold$105.00N/AView Rating Details
9/25/2017Raymond JamesReiterated RatingOutperform -> Market PerformHighView Rating Details
7/25/2017Bank of AmericaUpgradeNeutral -> Buy$111.00 -> $118.00MediumView Rating Details
7/19/2017BarclaysReiterated RatingHold$110.00LowView Rating Details
7/6/2017UBSBoost Price TargetBuy$115.00 -> $123.00N/AView Rating Details
4/23/2017Deutsche BankReiterated RatingBuy$108.00 -> $115.00LowView Rating Details
4/12/2017FBR & CoBoost Price TargetOutperform$103.00 -> $110.00LowView Rating Details
6/24/2016Jyske BankDowngradeNeutral -> SellN/AView Rating Details
5/16/2016Robert W. BairdReiterated RatingHoldN/AView Rating Details
4/22/2016Royal Bank of CanadaBoost Price TargetSector Perform$70.00 -> $76.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Quest Diagnostics (NYSE:DGX) Earnings History and Estimates Chart

Earnings by Quarter for Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) Earnings Estimates

2018 EPS Consensus Estimate: $6.17
2019 EPS Consensus Estimate: $6.51
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$1.31$1.41$1.37
Q2 20184$1.52$1.80$1.63
Q3 20184$1.53$1.73$1.61
Q4 20184$1.44$1.68$1.56
Q1 20192$1.39$1.55$1.47
Q2 20193$1.58$1.83$1.70
Q3 20193$1.59$1.76$1.67
Q4 20192$1.66$1.69$1.68

Quest Diagnostics (NYSE DGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/19/2018Q1 2018$1.47N/AView Earnings Details
2/1/2018Q4 2017$1.37$1.40$1.9342 billion$1.9360 billionViewN/AView Earnings Details
10/19/2017Q3 2017$1.35$1.39$1.9203 billion$1.9310 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.42$1.55$1.9444 billion$1.9430 billionViewN/AView Earnings Details
4/20/2017Q1 2017$1.1750$1.33$1.8675 billion$1.8990 billionViewN/AView Earnings Details
1/26/2017Q416$1.27$1.31$1.86 billion$1.86 billionViewListenView Earnings Details
10/20/2016Q316$1.35$1.37$1.53 billion$1.89 billionViewListenView Earnings Details
7/21/2016Q216$1.32$1.34$1.91 billion$1.91 billionViewListenView Earnings Details
4/21/2016Q116$1.12$1.12$1.82 billion$1.86 billionViewListenView Earnings Details
1/28/2016Q415$1.19$1.19$1.85 billion$1.85 billionViewListenView Earnings Details
10/22/2015Q315$1.26$1.28$1.89 billion$1.88 billionViewListenView Earnings Details
7/23/2015Q215$1.23$1.25$1.93 billion$1.93 billionViewListenView Earnings Details
4/23/2015Q115$1.04$1.05$1.85 billion$1.84 billionViewListenView Earnings Details
1/29/2015Q414$1.05$1.08$1.85 billion$1.90 billionViewListenView Earnings Details
10/23/2014Q314$1.08$1.10$1.87 billion$1.90 billionViewListenView Earnings Details
7/24/2014Q214$1.06$1.08$1.88 billion$1.90 billionViewN/AView Earnings Details
4/24/2014Q114$0.89$0.84$1.75 billion$1.75 billionViewListenView Earnings Details
1/30/2014Q413$0.93$0.97$1.74 billion$1.76 billionViewListenView Earnings Details
10/17/2013Q313$1.20$1.02$1.84 billion$1.79 billionViewListenView Earnings Details
7/18/2013Q2 2013$1.10$1.06$1.84 billion$1.8150 billionViewListenView Earnings Details
4/17/2013Q1 2013$1.03$0.89$1.86 billion$1.80 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.02$1.01$1.83 billion$1.77 billionViewListenView Earnings Details
10/17/2012$1.18$1.18ViewN/AView Earnings Details
7/19/2012$1.17$1.17ViewN/AView Earnings Details
4/18/2012$1.01$1.07ViewN/AView Earnings Details
1/24/2012$1.06$1.23ViewN/AView Earnings Details
10/25/2011$1.11$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$1.01$1.00ViewN/AView Earnings Details
1/25/2011$0.91$0.98ViewN/AView Earnings Details
10/20/2010Q3 2010$1.00$1.05ViewN/AView Earnings Details
7/21/2010Q2 2010$1.06$1.07ViewN/AView Earnings Details
4/21/2010Q1 2010$0.98$0.89ViewN/AView Earnings Details
1/25/2010Q4 2009$0.96$0.98ViewN/AView Earnings Details
10/20/2009Q3 2009$0.96$1.02ViewN/AView Earnings Details
7/21/2009Q2 2009$0.94$1.00ViewN/AView Earnings Details
4/21/2009Q1 2009$0.82$0.89ViewN/AView Earnings Details
1/26/2009Q4 2008$0.80$0.87ViewN/AView Earnings Details
10/21/2008Q3 2008$0.81$0.86ViewN/AView Earnings Details
7/22/2008Q2 2008$0.78$0.83ViewN/AView Earnings Details
4/21/2008Q1 2008$0.70$0.72ViewN/AView Earnings Details
2/21/2008Q4 2007$0.78$0.79ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Quest Diagnostics (NYSE:DGX) Dividend Information

Quest Diagnostics pays an annual dividend of $2.00 per share, with a dividend yield of 1.98%. DGX's most recent quarterly dividend payment was Wednesday, April 18. The company has grown its dividend for the last 6 consecutive years and is increasing its dividend by an average of 11.70% each year. Quest Diagnostics pays out 37.04% of its earnings out as a dividend.
Most Recent Dividend:4/18/2018
Annual Dividend:$2.00
Dividend Yield:1.98%
Dividend Growth:11.70% (3 Year Average)
Payout Ratio:37.04% (Trailing 12 Months of Earnings)
30.35% (Based on This Year's Estimates)
29.11% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/1/2018quarterly$0.501.99%4/3/20184/4/20184/18/2018
11/29/2017quarterly$0.451.83%1/8/20181/9/20181/24/2018
8/18/2017quarterly$0.451.72%10/2/201710/3/201710/18/2017
5/16/2017quarterly$0.451.71%7/6/20177/10/20177/24/2017
2/21/2017quarterly$0.451.88%4/3/20174/5/20174/19/2017
11/11/2016quarterly$0.451/6/20171/10/20171/25/2017
8/17/2016quarterly$0.401.88%9/30/201610/4/201610/19/2016
5/18/2016quarterly$0.402.1%7/1/20167/6/20167/20/2016
1/28/2016quarterly$0.402.31%4/4/20164/6/20164/20/2016
12/4/2015quarterly$0.382.22%1/8/20161/12/20161/27/2016
8/18/2015quarterly$0.382.07%10/2/201510/6/201510/21/2015
5/15/2015quarterly$0.382.09%7/6/20157/8/20157/22/2015
1/29/2015quarterly$0.382.13%4/6/20154/8/20154/22/2015
12/4/2014quarterly$0.332.03%1/9/20151/13/20151/28/2015
8/15/2014quarterly$0.332.14%10/3/201410/7/201410/22/2014
5/21/2014quarterly$0.332.3%7/7/20147/9/20147/23/2014
1/30/2014quarterly$0.332.51%4/4/20144/8/20144/23/2014
12/6/2013quarterly$0.301.99%1/3/20141/7/20141/22/2014
8/20/2013quarterly$0.302.03%9/27/201310/1/201310/16/2013
5/21/2013quarterly$0.301.96%6/28/20137/2/20137/17/2013
2/26/2013quarterly$0.302.14%3/28/20134/2/20134/16/2013
(Data available from 1/1/2013 forward)

Insider Trades

Quest Diagnostics (NYSE DGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.79%
Institutional Ownership Percentage: 88.64%
Insider Trading History for Quest Diagnostics (NYSE:DGX)
Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE DGX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2018Jon R CohenSVPSell83,669$104.20$8,718,309.80115,426View SEC Filing  
3/5/2018Catherine T DohertySVPSell5,556$101.00$561,156.0078,890View SEC Filing  
3/5/2018J. E DavisEVPSell5,122$101.00$517,322.0048,909View SEC Filing  
2/28/2018Catherine T DohertySVPSell1,820$104.38$189,971.60View SEC Filing  
2/28/2018J. E DavisEVPSell1,798$104.42$187,747.16View SEC Filing  
2/26/2018Catherine T DohertySVPSell397$102.74$40,787.7871,926View SEC Filing  
2/26/2018J. E DavisEVPSell494$102.74$50,753.5641,691View SEC Filing  
2/26/2018Robert A KlugVPSell1,157$103.66$119,934.625,137View SEC Filing  
1/29/2018Stephen H RusckowskiChairmanSell106,840$107.00$11,431,880.00272,956View SEC Filing  
1/24/2018Catherine T DohertySVPSell21,294$104.00$2,214,576.0090,709View SEC Filing  
1/2/2018J. E DavisEVPSell63,880$98.68$6,303,678.40101,423View SEC Filing  
9/12/2017Stephen H RusckowskiChairmanSell59,235$108.16$6,406,857.60220,049View SEC Filing  
9/11/2017Daniel StanzioneDirectorSell40,900$108.07$4,420,063.0041,991View SEC Filing  
9/11/2017Stephen H RusckowskiCEOSell53,933$108.16$5,833,393.28220,049View SEC Filing  
9/5/2017Daniel StanzioneDirectorSell3,803$108.01$410,762.0335,359View SEC Filing  
9/5/2017Stephen H RusckowskiChairmanSell2,525$108.03$272,775.75168,413View SEC Filing  
8/4/2017Jeffrey M LeidenDirectorSell296$106.66$31,571.366,000View SEC Filing  
7/27/2017Jeffrey M LeidenDirectorSell1,304$108.73$141,783.926,296View SEC Filing  
6/19/2017Catherine T DohertySVPSell59,762$107.55$6,427,403.1078,582View SEC Filing  
4/24/2017Jenne K BritellDirectorSell6,111$104.03$635,727.33View SEC Filing  
4/20/2017Michael E PrevoznikSVPSell29,513$100.00$2,951,300.0041,335View SEC Filing  
3/16/2017Michael E PrevoznikSVPSell13,987$100.00$1,398,700.0054,309View SEC Filing  
3/3/2017Catherine T DohertySVPSell7,162$98.28$703,881.3687,809View SEC Filing  
2/27/2017Michael E PrevoznikSVPSell440$97.39$42,851.6041,734View SEC Filing  
1/30/2017Catherine T DohertySVPSell80,000$90.58$7,246,400.00119,321View SEC Filing  
8/19/2016Jenne K BritellDirectorSell4,000$84.76$339,040.00View SEC Filing  
8/10/2016Jenne K BritellDirectorSell4,000$85.20$340,800.00View SEC Filing  
8/3/2016Jeffrey M LeidenDirectorSell6,345$85.62$543,258.907,233View SEC Filing  
7/25/2016John B. ZieglerDirectorSell1,000$84.36$84,360.00View SEC Filing  
5/27/2016Catherine T DohertySVPSell47,334$77.27$3,657,498.18100,402View SEC Filing  
5/12/2016Jenne K BritellDirectorSell8,000$75.68$605,440.006,025View SEC Filing  
5/9/2016Everett CunninghamSVPSell56,312$76.26$4,294,353.1274,949View SEC Filing  
5/6/2016Everett CunninghamSVPSell50,447$76.00$3,833,972.0032,649View SEC Filing  
4/25/2016Catherine T DohertySVPSell29,550$74.45$2,199,997.50106,285View SEC Filing  
3/3/2015Michael E PrevoznikSVPSell3,261$71.16$232,052.76View SEC Filing  
2/11/2015Daniel StanzioneDirectorSell8,000$70.97$567,760.00View SEC Filing  
2/4/2015Gail R WilenskyDirectorSell8,000$72.34$578,720.00View SEC Filing  
2/3/2015John B ZieglerDirectorSell8,000$71.88$575,040.00View SEC Filing  
2/2/2015Thomas F BongiornoVPSell3,000$71.50$214,500.00View SEC Filing  
11/17/2014Jon R CohenSVPSell160,029$63.13$10,102,630.77View SEC Filing  
8/8/2014Catherine T DohertySVPSell25,000$60.12$1,503,000.00View SEC Filing  
8/4/2014Michael E PrevoznikSVPSell14,377$61.01$877,140.77View SEC Filing  
7/30/2014Jenne K BritellDirectorSell8,000$62.37$498,960.00View SEC Filing  
7/30/2014Michael E PrevoznikSVPSell16,384$62.51$1,024,163.84View SEC Filing  
7/29/2014John C Md BaldwinDirectorSell8,000$62.31$498,480.00View SEC Filing  
7/28/2014Thomas F BongiornoVPSell4,000$61.72$246,880.00View SEC Filing  
7/25/2014John B ZieglerDirectorSell8,000$61.90$495,200.00View SEC Filing  
5/22/2014John ZieglerDirectorSell2,973$57.65$171,393.4516,825View SEC Filing  
5/7/2014Gary PfeifferDirectorSell10,000$55.95$559,500.0013,927View SEC Filing  
5/5/2014Mark GuinanCFOBuy4,000$55.51$222,040.0044,222View SEC Filing  
2/27/2014Jenne BritellDirectorSell10,000$52.74$527,400.0012,227View SEC Filing  
2/19/2014Michael PrevoznikSVPSell2,860$52.26$149,463.6045,762View SEC Filing  
2/18/2014Gail WilenskyDirectorSell30,000$52.93$1,587,900.0015,927View SEC Filing  
2/6/2014Timothy MainDirectorBuy5,000$50.71$253,550.005,658View SEC Filing  
11/5/2013Thomas F BongiornoVPSell16,667$62.49$1,041,520.83View SEC Filing  
10/29/2013Thomas F BongiornoVPSell6,000$59.00$354,000.00View SEC Filing  
10/25/2013Gary M PfeifferDirectorSell2,000$58.10$116,200.00View SEC Filing  
9/17/2013Catherine DohertySVPSell43,334$62.00$2,686,708.0072,295View SEC Filing  
8/14/2013Catherine DohertySVPSell33,000$59.85$1,975,050.0072,290View SEC Filing  
8/12/2013John ZieglerDirectorSell1,953$59.45$116,105.8515,876View SEC Filing  
8/8/2013Thomas BongiornoVPSell10,864$59.33$644,561.1214,086View SEC Filing  
7/23/2013Jenne K BritellDirectorSell4,200$58.99$247,758.00View SEC Filing  
6/18/2013Michael E PrevoznikSVPSell126,667$62.64$7,934,420.88View SEC Filing  
5/22/2013John B ZieglerDirectorSell31,362$62.00$1,944,444.00View SEC Filing  
5/14/2013John C Md BaldwinDirectorSell1,214$59.41$72,123.74View SEC Filing  
4/11/2013John B ZieglerDirectorSell1,470$58.35$85,774.50View SEC Filing  
1/17/2013Gary M PfeifferDirectorSell10,000$60.00$600,000.00View SEC Filing  
10/3/2012Robert HagemannCFOSell46,667$64.00$2,986,688.00View SEC Filing  
8/7/2012Stephen H RusckowskiCEOBuy5,000$59.34$296,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Quest Diagnostics (NYSE DGX) News Headlines

Source:
DateHeadline
Static UnitedHealth Group Inc Stock Doesnt Offer Much UpsideStatic UnitedHealth Group Inc Stock Doesn't Offer Much Upside
investorplace.com - April 18 at 5:54 PM
BidaskClub Lowers Quest Diagnostics (DGX) to BuyBidaskClub Lowers Quest Diagnostics (DGX) to Buy
www.americanbankingnews.com - April 18 at 12:16 PM
Quest Diagnostics (DGX) Raised to Buy at Zacks Investment ResearchQuest Diagnostics (DGX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:12 AM
Barclays Reiterates Hold Rating for Quest Diagnostics (DGX)Barclays Reiterates Hold Rating for Quest Diagnostics (DGX)
www.americanbankingnews.com - April 17 at 4:47 PM
Quest Diagnostics (DGX) Cut to Hold at BidaskClubQuest Diagnostics (DGX) Cut to Hold at BidaskClub
www.americanbankingnews.com - April 16 at 7:00 PM
Bank of America Upgrades Quest Diagnostics (DGX) to "Buy"Bank of America Upgrades Quest Diagnostics (DGX) to "Buy"
www.americanbankingnews.com - April 16 at 12:37 PM
Quest Diagnostics (DGX) Upgraded to "Buy" by Zacks Investment ResearchQuest Diagnostics (DGX) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 15 at 7:21 PM
Quest Diagnostics (DGX) Receives Consensus Rating of "Hold" from AnalystsQuest Diagnostics (DGX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 2:01 PM
Quest Diagnostics (DGX) Expected to Announce Quarterly Sales of $1.91 BillionQuest Diagnostics (DGX) Expected to Announce Quarterly Sales of $1.91 Billion
www.americanbankingnews.com - April 15 at 4:29 AM
Zacks: Analysts Anticipate Quest Diagnostics (DGX) to Post $1.53 Earnings Per ShareZacks: Analysts Anticipate Quest Diagnostics (DGX) to Post $1.53 Earnings Per Share
www.americanbankingnews.com - April 13 at 9:31 AM
Quest Diagnostics (DGX) Set to Announce Earnings on ThursdayQuest Diagnostics (DGX) Set to Announce Earnings on Thursday
www.americanbankingnews.com - April 12 at 1:24 AM
Quest Diagnostics (DGX) Downgraded by BidaskClub to "Sell"Quest Diagnostics (DGX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 11 at 10:10 PM
Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?
finance.yahoo.com - April 10 at 5:46 PM
Quest Diagnostics (DGX) Upgraded at BidaskClubQuest Diagnostics (DGX) Upgraded at BidaskClub
www.americanbankingnews.com - April 10 at 12:30 PM
Big Healthcare Companies Jump Into Blockchain -- but Dont Expect Their Stocks to Soar Because of ItBig Healthcare Companies Jump Into Blockchain -- but Don't Expect Their Stocks to Soar Because of It
finance.yahoo.com - April 10 at 8:04 AM
Big Healthcare Companies Jump Into Blockchain -- but Don't Expect Their Stocks to Soar Because of ItBig Healthcare Companies Jump Into Blockchain -- but Don't Expect Their Stocks to Soar Because of It
finance.yahoo.com - April 10 at 8:04 AM
New Survey: False Beliefs about Sexual Risk, Poor Physician-Patient Communication May Impede STD Screening in Young WomenNew Survey: False Beliefs about Sexual Risk, Poor Physician-Patient Communication May Impede STD Screening in Young Women
finance.yahoo.com - April 9 at 5:37 PM
ValuEngine Lowers Quest Diagnostics (DGX) to HoldValuEngine Lowers Quest Diagnostics (DGX) to Hold
www.americanbankingnews.com - April 8 at 7:34 PM
Quest Diagnostics (DGX) Downgraded to "Sell" at Zacks Investment ResearchQuest Diagnostics (DGX) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 8 at 10:49 AM
Quest Diagnostics (DGX) Given a $105.00 Price Target at SunTrust BanksQuest Diagnostics (DGX) Given a $105.00 Price Target at SunTrust Banks
www.americanbankingnews.com - April 7 at 12:39 PM
Quest Diagnostics to Release First Quarter 2018 Financial Results on April 19Quest Diagnostics to Release First Quarter 2018 Financial Results on April 19
finance.yahoo.com - April 6 at 5:57 PM
Reviewing ELEKTA (EKTAY) & Quest Diagnostics (DGX)Reviewing ELEKTA (EKTAY) & Quest Diagnostics (DGX)
www.americanbankingnews.com - April 6 at 3:23 PM
OpGen (OPGN) & Quest Diagnostics (DGX) Head to Head ReviewOpGen (OPGN) & Quest Diagnostics (DGX) Head to Head Review
www.americanbankingnews.com - April 6 at 1:23 AM
Quest Diagnostics (DGX) Price Target Increased to $105.00 by Analysts at Canaccord GenuityQuest Diagnostics (DGX) Price Target Increased to $105.00 by Analysts at Canaccord Genuity
www.americanbankingnews.com - April 4 at 7:30 PM
Quest Diagnostics (DGX) Lowered to "Hold" at ValuEngineQuest Diagnostics (DGX) Lowered to "Hold" at ValuEngine
www.americanbankingnews.com - April 3 at 4:48 PM
Ex-Dividend Alert: Quest Diagnostics Boosted its Dividend By 11%; Will Trade Ex-Dividend on April 03, 2018Ex-Dividend Alert: Quest Diagnostics Boosted its Dividend By 11%; Will Trade Ex-Dividend on April 03, 2018
finance.yahoo.com - April 2 at 8:00 AM
Should Income Investors Buy Quest Diagnostics Incorporated (NYSE:DGX) Before Its Ex-Dividend?Should Income Investors Buy Quest Diagnostics Incorporated (NYSE:DGX) Before Its Ex-Dividend?
finance.yahoo.com - March 30 at 5:47 PM
Quest Diagnostics Inc (DGX) Expected to Announce Quarterly Sales of $1.91 BillionQuest Diagnostics Inc (DGX) Expected to Announce Quarterly Sales of $1.91 Billion
www.americanbankingnews.com - March 29 at 7:41 AM
Canaccord Genuity Reaffirms "Buy" Rating for Quest Diagnostics (DGX)Canaccord Genuity Reaffirms "Buy" Rating for Quest Diagnostics (DGX)
www.americanbankingnews.com - March 28 at 12:58 PM
Zacks: Brokerages Anticipate Quest Diagnostics Inc (DGX) to Announce $1.53 EPSZacks: Brokerages Anticipate Quest Diagnostics Inc (DGX) to Announce $1.53 EPS
www.americanbankingnews.com - March 27 at 9:14 AM
Piper Jaffray Companies Reaffirms "Hold" Rating for Quest Diagnostics (DGX)Piper Jaffray Companies Reaffirms "Hold" Rating for Quest Diagnostics (DGX)
www.americanbankingnews.com - March 25 at 9:48 PM
Is Quest Diagnostics a Great Stock for Value Investors? - NasdaqIs Quest Diagnostics a Great Stock for Value Investors? - Nasdaq
www.nasdaq.com - March 23 at 8:02 AM
Is Quest Diagnostics a Great Stock for Value Investors?Is Quest Diagnostics a Great Stock for Value Investors?
finance.yahoo.com - March 22 at 5:52 PM
Quest Diagnostics Inc (DGX) Given Consensus Recommendation of "Hold" by BrokeragesQuest Diagnostics Inc (DGX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 21 at 1:36 PM
5 Biggest Price Target Changes For Monday - Benzinga5 Biggest Price Target Changes For Monday - Benzinga
www.benzinga.com - March 20 at 8:05 AM
Quest Diagnostics (DGX) Price Target Raised to $115.00Quest Diagnostics (DGX) Price Target Raised to $115.00
www.americanbankingnews.com - March 19 at 12:00 PM
Why Theranos former president is fighting the SECs fraud charges related to its pitches to raise $700 million - San Francisco Business TimesWhy Theranos' former president is fighting the SEC's fraud charges related to its pitches to raise $700 million - San Francisco Business Times
www.bizjournals.com - March 17 at 8:03 AM
Quest Diagnostics (DGX) Upgraded to Equal Weight at Morgan StanleyQuest Diagnostics (DGX) Upgraded to Equal Weight at Morgan Stanley
www.americanbankingnews.com - March 15 at 12:58 AM
Quest Diagnostics (DGX) and Universal Health Services (UHS) Critical ComparisonQuest Diagnostics (DGX) and Universal Health Services (UHS) Critical Comparison
www.americanbankingnews.com - March 14 at 7:22 PM
Theranos, founder Elizabeth Holmes, former president charged with massive fraudTheranos, founder Elizabeth Holmes, former president charged with 'massive fraud'
www.bizjournals.com - March 14 at 5:57 PM
Morgan Stanley: Quest Diagnostics Has Balanced Risk-RewardMorgan Stanley: Quest Diagnostics Has Balanced Risk-Reward
finance.yahoo.com - March 14 at 5:57 PM
Insider Selling: Quest Diagnostics Inc (DGX) SVP Sells 83,669 Shares of StockInsider Selling: Quest Diagnostics Inc (DGX) SVP Sells 83,669 Shares of Stock
www.americanbankingnews.com - March 12 at 7:20 PM
Quest Diagnostics Inc (DGX) Expected to Post Earnings of $1.54 Per ShareQuest Diagnostics Inc (DGX) Expected to Post Earnings of $1.54 Per Share
www.americanbankingnews.com - March 10 at 3:32 AM
Analyzing TeamHealth (TMH) and Quest Diagnostics (DGX)Analyzing TeamHealth (TMH) and Quest Diagnostics (DGX)
www.americanbankingnews.com - March 9 at 9:36 PM
Quest Diagnostics Long-Term View Solid, Reimbursement a Woe - NasdaqQuest Diagnostics Long-Term View Solid, Reimbursement a Woe - Nasdaq
www.nasdaq.com - March 9 at 8:00 AM
Quest Diagnostics Long-Term View Solid, Reimbursement a WoeQuest Diagnostics Long-Term View Solid, Reimbursement a Woe
finance.yahoo.com - March 8 at 7:04 PM
Benzingas Top Upgrades, Downgrades For March 7, 2018 - BenzingaBenzinga's Top Upgrades, Downgrades For March 7, 2018 - Benzinga
www.benzinga.com - March 7 at 6:51 PM
Argus Upgrades Quest Diagnostics, Cites Several Key CatalystsArgus Upgrades Quest Diagnostics, Cites Several Key Catalysts
finance.yahoo.com - March 7 at 6:51 PM
Quest Diagnostics (DGX) Rating Increased to Buy at ArgusQuest Diagnostics (DGX) Rating Increased to Buy at Argus
www.americanbankingnews.com - March 7 at 5:21 PM
Zacks Investment Research Downgrades Quest Diagnostics (DGX) to HoldZacks Investment Research Downgrades Quest Diagnostics (DGX) to Hold
www.americanbankingnews.com - March 7 at 12:42 PM

SEC Filings

Quest Diagnostics (NYSE:DGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Quest Diagnostics (NYSE:DGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Quest Diagnostics (NYSE DGX) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.